title: Renal allograft re-use and herpetic re-infection.
abstract: A middle-aged man received a kidney transplant from a deceased multi-organ donor. The recipient suffered cardiac arrest several days post-operatively and sustained hypoxic brain injury and was declared brain dead. Following the family's consent, the allograft kidney was retrieved and re-transplanted into a man with end-stage renal failure secondary to reflux nephropathy. The liver was not transplanted due to suspicion of fatty changes based on macroscopic appearance. After transplantation of other organs, liver histology revealed coagulative parenchymal necrosis with nuclear inclusions and moderate parenchymal cholestasis, suggestive of herpes viral hepatitis. Renal implantation biopsy showed histiocytes with enlarged nuclei containing viral inclusions in the capsular fibrous tissue, with positive immunostaining for herpes simplex virus (HSV). Anti-viral therapy was commenced immediately after obtaining histological evidence of donor HSV infection. Our recipient had pre-formed immunoglobulin G antibodies to HSV-1 and HSV-2, and was immunoglobulin M negative pre-transplant. HSV viraemia was detected day 5 post-transplant with a viral load of 7688 copies/mL by polymerase chain reaction assay. The recipient completed a 30 day course of intravenous ganciclovir before switching to oral valganciclovir as standard cytomegalovirus prophylaxis. The HSV polymerase chain reaction became undetectable on day 7 of intravenous ganciclovir and has remained undetectable. The patient remains well 9 months post-transplant with an estimated glomerular filtration rate of 61 mL/min per 1.73 m(2). Although renal allograft re-use has been shown to be technically possible with a good outcome in this recipient, this does raise issues including assessment of allografts that have undergone repeated severe ischaemic insults and the potential of transmission of infections.
authors: Department of Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
authors: Stella
authors: S
authors: Setyapranata
authors: Stephen G
authors: SG
authors: Holt
authors: Kate J
authors: KJ
authors: Wiggins
authors: William R
authors: WR
authors: Mulley
authors: Peter G
authors: PG
authors: Kerr
authors: Anthony J
authors: AJ
authors: Landgren
authors: Damon P
authors: DP
authors: Eisen
authors: Andrew
authors: A
authors: Young
authors: Helen
authors: H
authors: Opdam
authors: Amanda
authors: A
authors: Robertson
authors: Khashayar
authors: K
authors: Asadi
authors: Peter D
authors: PD
authors: Hughes
mesh_terms: D064591:Allografts; D000998:Antiviral Agents / Q000008:administration & dosage; D001706:Biopsy; D046148:Donor Selection; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives; D006561:Herpes Simplex / Q000175:diagnosis / Q000188:drug therapy / Q000635:transmission* / Q000821:virology; D018258:Herpesvirus 2, Human / Q000472:pathogenicity*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012086:Reoperation; D013997:Time Factors; D016896:Treatment Outcome; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir
keywords: Re-transplantation; allograft re-use; herpes virus transmission